Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605954 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
NCT02605954 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 275 participants.
The verdict
NCT02605954, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.
Interventions
- DRUG E/C/F/TAF
- DRUG ABC/3TC
- DRUG Third Antiretroviral Agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2015-11-18 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605954
The ClinicalTrials.gov registry entry for NCT02605954 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which E/C/F/TAF is the first listed.
NCT02605954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02605954 about?
NCT02605954 is a clinical study titled "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults". The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agen...
What is the current status of trial NCT02605954?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2015-11-18. Estimated completion is 2018-01-24.
What interventions are being tested in trial NCT02605954?
The interventions under investigation include: E/C/F/TAF (DRUG), ABC/3TC (DRUG), Third Antiretroviral Agent (DRUG).
Who is sponsoring clinical trial NCT02605954?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.